Investor’s Toolkit: Key Ratios for Assessing Arcus Biosciences Inc (RCUS)’s Performance

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Arcus Biosciences Inc (NYSE: RCUS) closed the day trading at $15.64 up 4.62% from the previous closing price of $14.95. In other words, the price has increased by $4.62 from its previous closing price. On the day, 0.65 million shares were traded. RCUS stock price reached its highest trading level at $15.74 during the session, while it also had its lowest trading level at $14.8101.

Ratios:

For a better understanding of RCUS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.14 and its Current Ratio is at 5.14. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.

On October 11, 2022, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 27 ’24 when Jarrett Jennifer sold 11,551 shares for $17.55 per share. The transaction valued at 202,720 led to the insider holds 215,253 shares of the business.

Jarrett Jennifer sold 13,449 shares of RCUS for $240,941 on Mar 18 ’24. The Chief Operating Officer now owns 226,804 shares after completing the transaction at $17.92 per share. On Feb 27 ’24, another insider, Jarrett Jennifer, who serves as the Chief Operating Officer of the company, sold 34,070 shares for $20.11 each. As a result, the insider received 685,148 and left with 240,253 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1429926144 and an Enterprise Value of 471926176. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.79 while its Price-to-Book (P/B) ratio in mrq is 2.25. Its current Enterprise Value per Revenue stands at 1.911 whereas that against EBITDA is -1.788.

Stock Price History:

Over the past 52 weeks, RCUS has reached a high of $25.47, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is 2.29%, while the 200-Day Moving Average is calculated to be -3.66%.

Shares Statistics:

Over the past 3-months, RCUS traded about 705.54K shares per day on average, while over the past 10 days, RCUS traded about 633720 shares per day. A total of 75.50M shares are outstanding, with a floating share count of 48.50M. Insiders hold about 46.96% of the company’s shares, while institutions hold 55.66% stake in the company. Shares short for RCUS as of 1722384000 were 6620446 with a Short Ratio of 9.38, compared to 1719532800 on 6160794. Therefore, it implies a Short% of Shares Outstanding of 6620446 and a Short% of Float of 14.99.

Most Popular